SCHEMBL5875593

SCHEMBL5875593

NC(=O)c1ncc(S(=O)(=O)c2ccc(NCc3ccccc3)cc2)s1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.52
CA2 P00918 5/20 0.52
CA12 O43570 3/20 0.52
CA9 Q16790 3/20 0.52
LOXL2 Q9Y4K0 2/20 0.46
NAMPT P43490 3/20 0.44
JAK3 P52333 2/20 0.42
IRAK4 Q9NWZ3 2/20 0.42
CYP1A2 P05177 1/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
PRMT1 Q99873 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5875599 0.85 ADORA3 (0.58) CA1CA2CA12CA9LOXL2
SCHEMBL5875742 0.81 ADORA3 (0.47) LOXL2LMNAMAPTKMT2A
SCHEMBL5875752 0.76 ADORA3 (0.67) LOXL2PRMT1LMNAKMT2A
SCHEMBL5875686 0.75 ADORA3 (0.49) LOXL2LMNAMAPTKMT2A
SCHEMBL5875845 0.72 CRHBP (0.56) LMNAMAPTKMT2A
SCHEMBL9189617 0.70 CA1 (0.70) CA1CA2CA12CA9CYP1A2
Benzylsulfamide SCHEMBL49548 0.70 CA2 (1.00) CA1CA2CA12CA9CYP1A2
SCHEMBL19224557 0.70 LOXL2 (0.59) LOXL2
N-Benzylaniline SCHEMBL28146501 0.69 FFAR1 (0.62) CA1CA2CA12CA9CYP1A2
Benzylsulfamide SCHEMBL3648127 0.69 CA1 (0.97) CA1CA2CA12CA9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP CA1 1403/4885CA2 2707/4885CA12 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.